(Q33947154)

30 July 2017

1 reference

title

Profound suppression of hepatitis B virus replication with lamivudine (English)

1 reference

30 July 2017

1 reference

1 reference

1 reference

Lai CL

1

1 reference

30 July 2017

Yuen MF

series ordinal

2

1 reference

30 July 2017

publication date

1 July 2000

1 reference

Journal of Medical Virology

30 July 2017

published in

1 reference

30 July 2017

volume

61

1 reference

30 July 2017

issue

3

1 reference

30 July 2017

page(s)

367-373

1 reference

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C367%3A%3AAID-JMV15%3E3.0.CO%3B2-A

Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C367%3A%3AAID-JMV15%3E3.0.CO%3B2-A

Transcripts and the putative RNA pregenome of duck hepatitis B virus: implications for reverse transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C367%3A%3AAID-JMV15%3E3.0.CO%3B2-A

Cellular metabolism of (−) enantiomeric 2′-deoxy-3′-thiacytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C367%3A%3AAID-JMV15%3E3.0.CO%3B2-A

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C367%3A%3AAID-JMV15%3E3.0.CO%3B2-A

The long-term course of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C367%3A%3AAID-JMV15%3E3.0.CO%3B2-A

Immunopathogenesis of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C367%3A%3AAID-JMV15%3E3.0.CO%3B2-A

The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C367%3A%3AAID-JMV15%3E3.0.CO%3B2-A

Epidemiology of hepatitis B infection in the Western Pacific and South East Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C367%3A%3AAID-JMV15%3E3.0.CO%3B2-A

Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C367%3A%3AAID-JMV15%3E3.0.CO%3B2-A

Clinical pharmacokinetics of lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C367%3A%3AAID-JMV15%3E3.0.CO%3B2-A

Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C367%3A%3AAID-JMV15%3E3.0.CO%3B2-A

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C367%3A%3AAID-JMV15%3E3.0.CO%3B2-A

Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C367%3A%3AAID-JMV15%3E3.0.CO%3B2-A

Six years of sentinel surveillance of hepatitis B in general practice in France.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C367%3A%3AAID-JMV15%3E3.0.CO%3B2-A

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C367%3A%3AAID-JMV15%3E3.0.CO%3B2-A

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C367%3A%3AAID-JMV15%3E3.0.CO%3B2-A

Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C367%3A%3AAID-JMV15%3E3.0.CO%3B2-A

Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C367%3A%3AAID-JMV15%3E3.0.CO%3B2-A

Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C367%3A%3AAID-JMV15%3E3.0.CO%3B2-A

Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C367%3A%3AAID-JMV15%3E3.0.CO%3B2-A

More than third of world's population has been infected with hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C367%3A%3AAID-JMV15%3E3.0.CO%3B2-A

Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C367%3A%3AAID-JMV15%3E3.0.CO%3B2-A

PLACEBO-CONTROLLED TRIAL OF RECOMBINANT α2-INTERFERON IN CHINESE HBsAg-CARRIER CHILDREN

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C367%3A%3AAID-JMV15%3E3.0.CO%3B2-A

A controlled trial of interferon with or without prednisone priming for chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C367%3A%3AAID-JMV15%3E3.0.CO%3B2-A

Lamivudine as initial treatment for chronic hepatitis B in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C367%3A%3AAID-JMV15%3E3.0.CO%3B2-A

The pharmacokinetics of lamivudine in patients with impaired hepatic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C367%3A%3AAID-JMV15%3E3.0.CO%3B2-A

Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C367%3A%3AAID-JMV15%3E3.0.CO%3B2-A

Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-9071%28200007%2961%3A3%3C367%3A%3AAID-JMV15%3E3.0.CO%3B2-A

10.1002/1096-9071(200007)61:3<367::AID-JMV15>3.0.CO;2-A

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference